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INTRODUCTION
Heparan sulfate (HS)-containing proteoglycans in the extracellular matrix and at the cell surface play important roles in the regulation of protease activity, growth factor signaling and cell surface receptor-mediated endocytosis of various ligands (Mulloy and Rider et al., 2006; Christianson and Belting, 2014) . While little is understood regarding how these macromolecules contribute to disease one clue to their biological importance lies in a devastating group of inherited diseases involving impaired turnover of HS in lysosomes. Mucopolysaccharidosis III (MPS III; Sanfilippo syndrome) includes four biochemically distinct lysosomal storage diseases, each characterized by deficiency of a lysosomal enzyme involved in the step-wise degradation of HS (Neufeld and Muenzer, 2001) . Sanfilippo B exhibits an autosomal recessive mode of inheritance and arises from mutations in the NAGLU gene, which encodes -N-acetylglucosaminidase (NAGLU). In its severest form Sanfilippo B patients exhibit non-detectable or very low levels of NAGLU activity in their lysosomes, which coincides with lysosomal HS accumulation in the brain and ultimately leads to severe neurodegenerative disease and early death (Andrade et al., 2015; Yogalingam & Hopwood 2001) .
However, little is understood regarding the mechanism by which accumulation of HS in lysosomes leads to neurodegenerative disease in Sanfilippo syndrome.
Studies in a mouse model of Sanfilippo B suggest that neurons and astrocytes of the Sanfilippo B brain may be compromised as a consequence of elevated levels of HS (Li et al., 2002 , Ohmi et al., 2009 . HS accumulation in microglia is also thought to contribute to neurodegeneration associated with Sanfilippo B (Ohmi et al., 2003; Archer et al., 2014) . Developing therapeutic approaches to augment NAGLU activity in these critical cell types of neurodegenerative disease pathogenesis in Sanfilippo B may therefore be paramount for successful clearance of accumulated substrate, subsequently leading to correction of underlying pathology and stabilization of the disease.
In most cases of Sanfilippo B and other MPS disorders, the entire range of clinical phenotypes ranging from severe to relatively mild are clustered within a 4 narrow range of residual lysosomal enzyme activity, from 0-20% of normal control levels (Yogalingam et al., 2000; Yogalingam et al., 1998; Crawley et al., 1998; Clark et al., 2018) . These genotype-phenotype correlations suggest that reduced levels of residual lysosomal enzyme activity, down to a critical "threshold", are sufficient to turn over substrate in vivo and prevent lysosomal storage disease and that small changes in residual activity below this threshold may lead to dramatic differences in the rate of substrate turn-over and the severity of the lysosomal storage disease (Conzelmann and Sandhoff, 1984) . Several approved products for MPS have exploited this phenomenon to develop lysosomal-targeted enzyme replacement therapies (ERT) to augment residual lysosomal enzyme activity in patients, resulting in substrate reduction and improved quality of life (Poswar et al., 2017) . These ERT trials have utilized the cell surface insulin-like growth factor 2 (IGF2) / cation-independent mannose-6-phospate receptor (CI-MPR) targeting pathway, where phosphorylated glycans present on secreted lysosomal enzymes bind avidly to the CI-MPR, resulting in their internalization into clathrin-coated vesicles, and delivery to lysosomes of patient cells (Kornfeld, 1992) .
In the case of ERT development for Sanfilippo B, recombinant human NAGLU (rhNAGLU) over-expressed and secreted in Chinese hamster ovary (CHO) cells and in Sanfilippo B human fibroblasts is not mannose -6phosphorylated (Zhao and Neufeld, 2000; Yogalingam et al., 2000) , a property that may severely limit its uptake into key critical cellular targets of disease pathogenesis. Our group has therefore utilized a glycosylation independent lysosomal targeting (GILT) system, whereby IGF2 has been fused to rhNAGLU (rhNAGLU-IGF2; BMN 250) to mediate CI-MPR-mediated cellular uptake and delivery to lysosomes (LeBowitz et al., 2004 , Maga et al., 2013 Kan et al., 2014) . BMN 250 is a novel recombinant fusion protein currently being developed as an investigational ERT for Sanfilippo B. We have shown that intracerebroventricular (ICV) administration of BMN 250 in a knock-out mouse model and a naturally occurring dog model of Sanfilippo B can augment NAGLU activity and NAGLU protein levels in all cell types throughout the brain, normalize HS levels and reverse 5 several aspects of well-entrenched secondary neuropathology associated with the disease (Kan et al., 2014; Aoyagi-Scharber et al., 2017; Ellinwood et al., 2018) .
While normalization of HS levels in the Sanfilippo B mouse and dog brains with ICV-administered BMN 250 is indicative of successful enzyme delivery to critical cellular targets of Sanfilippo B disease pathogenesis, the cellular uptake mechanism/-s by which this process occurs in different cell types of the brain has yet to be demonstrated.
Here we performed a series of competitive cellular uptake assays with BMN 250 in primary human Sanfilippo B patient fibroblasts and normal rodent-derived neurons, astrocytes and microglia. These studies distinguish two pathways by which BMN 250 in the extracellular space can be delivered to lysosomes of cells to augment residual NAGLU activity. We demonstrate that GILT technology confers predominantly CI-MPR-mediated cellular uptake and delivery of BMN 250 to lysosomes in neurons, astrocytes and fibroblasts, whereas receptorindependent cellular uptake in microglia contributes to substantial lysosomal delivery of both BMN 250 and the untagged rhNAGLU. (Walkersville, MD). Astrocytes and microglia were enriched from postnatal day 2 normal rat total brain tissue were also obtained from ScienCell Research Laboratories (Carlsbad, CA). Neurons, astrocytes and microglia were cultured in poly-L-lysine-treated 96-well black tissue-culture-treated plates using defined medium, as recommended by the supplier.
METHODS

Cell lines:
6 Direct "in-plate" NAGLU activity determination: NAGLU activity levels in cells plated in 96-well plates, as described above, was determined using the using the 4MU substrate, 4-Methylumbelliferyl-N-acetyl-α-D-glucosaminide. Briefly, cells in each well were washed extensively then lysed at room temperature for 15 minutes with 57.5 uL of mammalian protein extraction reagent per well (M-PER;
ThermoFisher Scientific, Waltham, MA). Of this lysate, 10 uL was used to determine total protein levels using a BCA protein assay kit (ThermoFisher Scientific, Waltham, MA). The remaining lysate in each well was then incubated in the presence of 2 mM 4-Methylumbelliferyl-N-acetyl-α-D-glucosaminide in 0.2 M Acetate buffer pH 4.8 for 30 minutes at 37 o C in a total reaction volume of 85 uL.
The reactions were terminated by addition of 200 uL Glycine/NaOH buffer pH 10.7
to each well and plates were read at Ex360 Em460 with 455 cut off using a Spectramax i3 plate reader (Molecular Devices). A standard curve containing known amounts of 4-Methylumbelliferone (4-MU Standard; Sigma-Aldrich, St Louis, MO) was included in each assay to calculate NAGLU activity levels. In some instances where indicated, 4 uM IGF2 (Cell Sciences, Canton, MA) or 5 mM mannose-6-phophate (Man6P; Sigma-Aldrich, St Louis, MO) was added to uptake medium to competitively inhibit CI-MPR-mediated uptake of BMN 250.
Enzyme uptake studies: Recombinant human NAGLU-IGF2 fusion and NAGLU
proteins were expressed in Chinese hamster ovary cells and purified, as described elsewhere (US 9,376,480 B2; Kan et al., 2014) . To determine how much BMN 250 is required to normalize NAGLU activity, endogenous NAGLU activity in each normal primary neuron, astrocyte or microglia cell line was compared with BMN 250-specific NAGLU activity following a 24 hour exposure to 6.25 nM BMN 250 or 6.25 nM rhNAGLU in the presence of 4 uM IGF2. Following BMN 250 uptake, cell lysates were prepared and assayed for NAGLU activity as described above. To determine the fold-increase above normal levels arising from BMN 250 uptake or rhNAGLU uptake, NAGLU activity following enzyme uptake was compared with the normal endogenous NAGLU activity level in each cell line. 7 K uptake determination: To determine the K uptake , the concentration of enzyme mediating half-maximal uptake, cells were incubated with varying concentrations of enzyme over a 24 hour period (dose-range 0.195 nM→100), at which time the enzyme activity present in cells was plotted into a Michaelis-Menten curve using GraphPad Prism software (La Jolla, CA).
Immunofluorescence: BMN 250 uptake in primary cells was also monitored by imaging, where BMN 250 was directly conjugated with Alexa Fluor 488 (AF488) prior to uptake. BMN 250 was conjugated to AF488 using a 5 fold-molar excess of AF488 Sulfodichlorophenol Ester (Thermo Scientific A30052) and purified as described by the manufacturer, yielding approximately 3 fluorophores per molecule of BMN 250. NAGLU activity was tested before and after labeling to ensure that AF488 conjugation did not affect activity toward 4MU substrate (data not shown). Cells were incubated with 0.2 -0.4 uM LysoTracker Red prior to fixation to permit identification of acidified lysosomes.
Quantitative analysis of HS in MPSIIIB patient fibroblasts
Total heparan sulfate was quantified using a modification of the method previously described (Lawrence et al. 2012; Lawrence et al. 2008) . Total HS data is expressed as average pmoles total HS per ug total protein from triplicate sample wells per condition +/-SD.
RESULTS AND DISCUSSION
BMN 250 uptake is predominantly CI-MPR-mediated in mouse hippocampal neurons.
In normal mouse-derived hippocampal neurons, the majority of BMN250 uptake over 24 hours approximates Michaelis-Menten kinetics with a K uptake of 5 nM ( Figure 1A) . AF-488-tagged BMN 250 co-localizes with LysoTracker Red + acidified organelles in the cell body and along axonal projections of mouse neuronal hippocampal cells following cellular uptake, suggestive of successful 8 delivery to lysosomes (Figure 1C, 1D and 1E) . At the highest concentration tested (100 nM) NAGLU activity is increased by 13-fold, when compared with endogenous NAGLU activity detected in normal untreated mouse hippocampal neurons ( Figure 1B) . Furthermore, at this highest dose tested (100 nM) the majority of BMN 250 uptake in mouse hippocampal-derived neurons is inhibited in the presence of 4 uM IGF2, a competitive inhibitor of CI-MPR-mediated cellular uptake, suggesting that the majority of BMN 250 cellular uptake is CI-MPRmediated ( Figure 1B) . CI-MPR-independent BMN 250 cellular uptake in mouse hippocampal neurons is sufficient to augment NAGLU activity by 2.5-fold, when compared with endogenous NAGLU activity detected in untreated normal mouse hippocampal neurons ( Figure 1B) . The untagged rhNAGLU is also taken up into mouse hippocampal neurons at the highest nM concentration tested (100 nM), which is sufficient to augment NAGLU activity by 2.1-fold above normal levels in untreated normal hippocampal neurons ( Figure 1B) . Glycan analysis of CHOexpressed NAGLU-IGF2 and untagged rhNAGLU molecules have previously demonstrated the absence of phosphorylated glycans (Kan et al., 2014) . In support of this the addition of Man6P to the uptake medium does not inhibit uptake of rhNAGLU or BMN 250 ( Figure 1B) . These results suggest BMN 250 uptake is predominantly CI-MPR-mediated in mouse hippocampal-derived neurons, with receptor-independent uptake only becoming apparent at higher concentrations.
BMN 250 Uptake Into Rat Neurons and Astrocytes Is Predominantly CI-MPR-
Mediated, Whereas Uptake In Microglia Occurs Through CI-MPR-Mediated and Receptor-Independent Mechanisms.
BMN 250 cellular uptake was also evaluated in primary rat-derived neurons, astrocytes and microglia to permit comparison between three different cell types from the same species. NAGLU activity, standardized to total protein levels in each normal rat-derived cell line varies considerably, with comparatively higher levels of NAGLU activity being detected in normal rat-derived microglia (1120 ± 346 nmol/hr/mg), when compared with normal rat-derived cortical neurons (93 ± 23 nmol/hr/mg) and astrocytes (166 ± 12 nmol/hr/mg; Figure 2A) . A low-dose 9 exposure to 6.25 nM BMN 250 over 24 hours results in highly efficient cellular uptake of BMN 250 in all three primary rat cell lines, with 5-fold, 25-fold and 14fold increases in NAGLU activity above normal endogenous NAGLU activity levels detected in untreated rat neurons, astrocytes and microglia, respectively ( Figure   2B, 2C, 2D) . In contrast, NAGLU can only be detected in rat microglia following a 24 hour exposure to a low nM dose (6.25 nM) of the untagged rhNAGLU, with no NAGLU activity detected in rat derived neurons and astrocytes ( Figure 2B , C, D, respectively). Furthermore, the NAGLU activity that was detected in rat microglia following exposure to a low nM dose of untagged rhNAGLU was increased by 2.5fold over endogenous NAGLU activity detected in normal rat microglia ( Figure 2D ).
These results suggest that of the three primary cell rat lines tested, BMN 250 can normalize NAGLU activity in all three cell lines at low nM concentrations, whereas untagged rhNAGLU can only normalize NAGLU activity in microglia.
To determine the enzyme uptake capacity (V max ) for each rat-derived cell line a series of uptake curves were performed with increasing doses of BMN 250 or untagged rhNAGLU. As previously shown in ICV-ERT studies in Sanfilippo B mice (Aoyagi-Scharber et al., 2017) , of the three rat-derived primary cell type cultures tested, untagged rhNAGLU only shows appreciable uptake in microglial cells, with low or non-detectable uptake detected in cortical neurons and astrocytes ( Figure   3A ). In contrast, BMN 250 uptake can be readily detected in all three cell types over a 24 hour period ( Figure 3B) , with K uptake corresponding to 5 nM in cortical neurons, 3.4 nM in astrocytes and 2.6 nM in microglia ( Figure 3B ). These results are in agreement with our previous in vivo studies, with NAGLU protein being detected in neurons, astrocytes and microglia of the Sanfilppo B mouse brain following ICV administration of BMN 250 (Aoyagi-Scharber et al., 2017).
BMN 250 uptake capacity in microglia (V max =12,336 nmol/hr/mg; Figure 3B) exceeds the uptake capacity reached in cortical neurons (V max =764 nmol/hr/mg; Figure 3B ) and astrocytes (V max =5380 nmol/hr/mg; Figure 3B ). The majority of BMN 250 uptake into rat cortical neurons and astrocytes is blocked with the addition of 4 uM IGF2 to the uptake medium, (Figure 4A, 4B ), suggesting that BMN 250 uptake and delivery to lysosomes is predominantly CI-MPR-mediated. In contrast to rat neurons and rat astrocytes, rat microglia appear to possess a more efficient CI-MPR-independent uptake pathway, since the addition of 4 uM IGF2 to the uptake medium only partially inhibits the uptake of BMN 250 into rat microglia ( Figure 4C ). Receptor-independent uptake of BMN 250 in microglia plotted against enzyme concentration shows that the pattern of enzyme uptake does not reach saturation, further suggestive of receptor-independent uptake ( Figure 5B ).
Likewise, cellular uptake of the untagged rhNAGLU in rat microglia is also observed ( Figure 4C ), which contrasts with rhNAGLU uptake in rat neurons and astrocytes ( Figures 4A, 4B) . These results are suggestive of both CI-MPRmediated and receptor-independent mechanisms being utilized in the cellular uptake and lysosomal targeting of BMN 250 in rat-derived neurons, astrocytes and microglia, with the highest levels of receptor-independent uptake occurring in microglia.
BMN 250 Uptake In Sanfilippo B Patient Fibroblasts Is Predominantly CI-
MPR-Mediated And Is Sufficient To Prevent HS Accumulation.
Our results in primary neurons, astrocytes and microglia are suggestive of BMN 250 cellular uptake and delivery to lysosomes being mediated by both CI-MPRmediated and receptor-independent mechanisms to varying degrees, depending on the enzyme concentration and the cell type. To further understand the therapeutic relevance of CI-MPR-mediated BMN 250 uptake we utilized Sanfilippo B patient fibroblasts that are known to accumulate HS (Prill et al., Submitted) .
Similar to the uptake pattern observed in neurons and astrocytes, BMN 250 uptake in Sanfilippo B patient fibroblasts over 24 hours approximates Michaelis-Menten kinetics with a K uptake of 5.1 nM and is predominantly CI-MPR-mediated, since the majority of uptake can be inhibited with IGF2 ( Figure 6 ). Receptor independent uptake is observed at the higher concentrations ( Figure 6 ) and is similar to uptake of untagged rhNAGLU ( Figure 6 ).
Incubation of Sanfilippo B patient fibroblasts with concentrations of BMN
250 at or below the 5.1 nM K uptake (1.56, 3.125 or 6.25 nM BMN 250) for 2 hours, followed by 10 days of culture results in dose-dependent increases in NAGLU activity, corresponding to 8%, 16% and 21% of normal NAGLU activity levels detected in fibroblasts from a health control individual, respectively ( Figure 7A ). Uptake of BMN 250 coincides with dose-dependent reduction in the amount of HS accumulation ( Figure 7A ). Furthermore, at the highest concentration of BMN 250 tested (6.25 nM), HS levels are completely cleared, suggestive of successful delivery of BMN 250 to lysosomes of Sanfilippo B patient fibroblasts ( Figure 7A ).
In support of this AF488-labeled BMN 250 co-localizes with LysoTracker Red + organelles following cellular uptake in Sanfilippo B patient fibroblasts ( Figure 7C ).
In contrast, untagged rhNAGLU does not exhibit cellular uptake in Sanfilippo B patient fibroblasts at the same concentrations tested (1.56 nM, 3.125 nM and 6.25 nM), which coincides with no reduction in HS storage ( Figure 7B ).
In conclusion, our results suggest that while untagged rhNAGLU exhibits efficient receptor-independent cellular uptake into microglia, negligible uptake of untagged rhNAGLU is observed in cultured neurons or astrocytes. BMN 250, an IGF2-tagged NAGLU molecule, overcomes this obstacle by permitting highly efficient CI-MPR-mediated cellular uptake and lysosomal delivery of NAGLU into neurons and astrocytes. Furthermore, only BMN 250 can mediate clearance of HS storage in primary cultures of Sanfilippo B mouse-derived neurons and astrocytes when exposed to very low nM concentrations (Prill et al., submitted) , a phenomenon which may potentially occur at sites of the Sanfilippo B brain that are distal to the site of ICV-administered enzyme. If clearance of HS from neurons and astrocytes throughout the brain is critical for treatment of Sanfilippo B, then an efficient targeting mechanism such as that possessed by BMN 250 will be critical for successful treatment of this disease. repeats). BMN 250 K uptake in rat cortical neurons = 6.0 nM, V max = 1,040 nmol/hr/mg; BMN 250 K uptake in astrocytes = 3.5 nM, V max = 5,404 nmol/hr/mg; BMN 250 K uptake in microglia = 2.6 nM, V max = 12,336 nmol/hr/mg; BMN 250 K uptake in microglia in the presence of 4 uM IGF2 = 19.7 nM, V max = 5028 nmol/hr/mg; rhNAGLU K uptake in microglia = 4.1 nM; V max = 5355 nmol/hr/mg. activity detected is representative of three replicate cultures. Corresponding levels of HS detected at each enzyme concentration using SensiPro assay are indicated with black circles. NAGLU activity was augmented by 8%, 16% and 21% of normal NAGLU activity levels following incubation with 1.56 nM, 3.125, and 6.25 nM BMN 250, respectively, which coincides with near-to-complete clearance of HS. C.
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